Tumor suppressor that is a key regulator of the G1/S transition of the cell cycle (PubMed:10499802). The hypophosphorylated form binds transcription regulators of the E2F family, preventing transcription of E2F-responsive genes (PubMed:10499802). Both physically blocks E2Fs transactivating domain and recruits chromatin-modifying enzymes that actively repress transcription (PubMed:10499802).
Cyclin and CDK-dependent phosphorylation of RB1 induces its dissociation from E2Fs, thereby activating transcription of E2F responsive genes and triggering entry into S phase (PubMed:10499802). RB1 also promotes the G0-G1 transition upon phosphorylation and activation by CDK3/cyclin-C (PubMed:15084261). Directly involved in heterochromatin formation by maintaining overall chromatin structure and, in particular, that of constitutive heterochromatin by stabilizing histone methylation.
Recruits and targets histone methyltransferases SUV39H1, KMT5B and KMT5C, leading to epigenetic transcriptional repression. Controls histone H4 'Lys-20' trimethylation. Inhibits the intrinsic kinase activity of TAF1.
Mediates transcriptional repression by SMARCA4/BRG1 by recruiting a histone deacetylase (HDAC) complex to the c-FOS promoter. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex (By similarity)
The hypophosphorylated form interacts with and sequesters the E2F1 transcription factor, thereby inhibiting E2F1 transcription (PubMed:20940255, PubMed:8336704). Interacts with heterodimeric E2F/DP transcription factor complexes containing TFDP1 and either E2F1, E2F3, E2F4 or E2F5, or TFDP2 and E2F4. Interacts (when hyperphosphorylated and hypophosphorylated) with PKP3; the interaction inhibits RB1 interaction with and repression of the transcription factor E2F1, potentially via sequestering RB1 to the cytoplasm (By similarity).
The unphosphorylated form interacts with EID1, ARID3B, KDM5A, SUV39H1, MJD2A/JHDM3A and THOC1. Interacts with the N-terminal domain of TAF1. Interacts with SNW1, ATAD5, AATF, DNMT1, LIN9, LMNA, KMT5B, KMT5C, PELP1, UHRF2 and TMPO-alpha.
Interacts with GRIP1 and UBR4. Interacts with ARID4A and KDM5B. Interacts with E4F1 and LIMD1.
Interacts with SMARCA4/BRG1 and HDAC1 (By similarity). Interacts with PSMA3 and USP4. Interacts (when methylated at Lys-860) with L3MBTL1.
Interacts with CHEK2; phosphorylates RB1. Interacts with CDK1 and CDK2 (By similarity). Interacts with PRMT2.
Interacts with CEBPA (PubMed:15107404). P-TEFB complex interacts with RB1; promotes phosphorylation of RB1 (PubMed:12037672). Interacts with RBBP9; the interaction disrupts RB1 binding to E2F1 (By similarity).
Interacts with KAT2B/PCAF and EP300/P300 (By similarity). Interacts with PAX5 (PubMed:10197586). Interacts (phosphorylated and unphosphorylated) with BLCAP (PubMed:26986503).
May interact with NDC80
(Microbial infection) Interacts with adenovirus E1A protein
(Microbial infection) Interacts with HPV E7 protein
(Microbial infection) Interacts with SV40 large T antigen
(Microbial infection) Interacts with human cytomegalovirus/HHV-5 proteins UL82 and UL123
(Microbial infection) Interacts with molluscum contagiosum virus protein MC007
Expressed in the retina. Expressed in foreskin keratinocytes (at protein level) (PubMed:20940255)
The Pocket domain binds to the threonine-phosphorylated domain C, thereby preventing interaction with heterodimeric E2F/DP transcription factor complexes
Congenital malignant tumor that arises from the nuclear layers of the retina. It occurs in about 1:20'000 live births and represents about 2% of childhood malignancies. It is bilateral in about 30% of cases.
Although most RB appear sporadically, about 20% are transmitted as an autosomal dominant trait with incomplete penetrance. The diagnosis is usually made before the age of 2 years when strabismus or a gray to yellow reflex from pupil ('cat eye') is investigated.
A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder.
Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.
A sarcoma originating in bone-forming cells, affecting the ends of long bones.
No mutation information available.
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to ADARB1, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 4
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT03450590 | Parasympathetic Cardiovascular Function Disorder | Heart Rate Variability and Cardiorespiratory Complications During Ophthalmic Arterial Chemotherapy for Retinoblastoma | N/A | COMPLETED |
| NCT00091182 | Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor, Childhood Hepatoblastoma, Childhood Hepatocellular Carcinoma, Childhood High-grade Cerebral Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Malignant Ovarian Germ Cell Tumor, Childhood Malignant Testicular Germ Cell Tumor, Childhood Teratoma, Recurrent Adrenocortical Carcinoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Colon Cancer, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Nasopharyngeal Cancer, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer | Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment | PHASE2 | COMPLETED |
| NCT03139318 | Osteosarcoma in Children, Radiation Toxicity | Phase I Clinical Trial of GRID Therapy in Pediatric Osteosarcoma of the Extremity | NA | TERMINATED |
| NCT00003597 | Cancer | Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors | PHASE1 | COMPLETED |
| NCT07066982 | Sarcoma, Sarcoma, Kaposi, Sarcoma, Ewing, Sarcoma,Soft Tissue, Sarcoma of Bone and Connective Tissue, Sarcoma, Synovial, Sarcoma Metastatic, Sarcomas, Germinoblastic, Sarcoma of Bone | Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas | PHASE1, PHASE2 | RECRUITING |
| NCT03604783 | Advanced Solid Tumors, Sarcoma, Ewing Sarcoma, Dedifferentiated Liposarcoma, Synovial Sarcoma | Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors | PHASE1 | TERMINATED |
| NCT00634322 | Osteosarcoma | High Dose Methotrexate With Leucovorin Rescue With or Without Glucarpidase in Osteosarcoma | PHASE2 | TERMINATED |
| NCT04365660 | Osteosarcoma | 18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma | PHASE2 | TERMINATED |
| NCT04544995 | Neoplasms | Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP) | PHASE1 | TERMINATED |
| NCT04945512 | Osteosarcoma, Analgesia | Efficacy of Epidural Analgesia in Lower Extremity Osteosarcoma | NA | UNKNOWN |